Navigation Links
FDA Issues Draft Guidance on Priority Review Vouchers

-BIO Ventures for Global Health to Work with Industry to Educate, Promote PRV Program-

WASHINGTON, Oct. 20 /PRNewswire-USNewswire/ -- BIO Ventures for Global Health (BVGH) today announced its support of the US Food and Drug Administration's (FDA) release of Draft Guidance for Industry on Priority Review Vouchers. The Priority Review Voucher (PRV) program is designed to encourage industry investment in the development of drugs and vaccines for neglected tropical diseases. Enacted as part of the FDA Amendments Act, the program awards a Priority Review Voucher to any sponsor obtaining FDA approval for a product preventing or treating diseases such as malaria, tuberculosis and leishmaniasis. The voucher, which can be traded or sold, can be used to obtain priority review on a future product of the company's choosing, shaving months off the standard FDA review.

Barriers such as insufficient markets, funding, and information have largely deterred industry from applying their technologies to research and development in this arena. PRVs can help industry overcome some of these barriers.

"Priority Review Vouchers are valuable incentives that leverage industry expertise and encourage greater investment in innovation for neglected tropical diseases," said Christopher D. Earl, president and CEO of BVGH. "By taking advantage of existing market forces, patients in the developing world can have faster access to lifesaving products that may not otherwise be developed. And sponsors of neglected disease drugs can be rewarded for their innovations."

Some economists estimate that a voucher may be worth hundreds of millions of dollars - an amount sufficient to offset the substantial risk and investment required for discovery and development of a new neglected disease product.

"Industry and investors alike are keenly following the implementation of the PRV program," said Wendy Taylor, founder and vice president of strategy and operations at BVGH. "The timely release of this guidance reinforces FDA's support of this important program."

A key aspect of the voucher is its ability to be traded or sold. The guidance confirms that contractual agreements directing the right to transfer vouchers can allow for an unlimited number of transfers before the voucher is used.

BVGH's support for PRVs stems from the organization's core mission in developing market-based incentives for investment in global health. BVGH is continuing its advocacy with industry and communication with all stakeholders to ensure that the PRV program grows into a powerful incentive for building the arsenal of new medicines for global health.

About BVGH

BIO Ventures for Global Health (BVGH), a non-profit organization, is harnessing the resources of the biotechnology industry to create new medicines for neglected diseases of the developing world. Our mission is to break down barriers that hinder industry involvement in global health product development and to catalyze new industry investment. For further information visit the BVGH website at:

SOURCE BIO Ventures for Global Health
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Resverlogix Issues a Management Statement
2. Issues MarketStats on Agri-Biotech Equities YGYB, GRO, SEED, MON, ADM, and BG
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
4. Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
5. Arbitration Panel Issues Ruling in Distribution Dispute
6. ActivBiotics Assignee Issues First Distribution of Cash to Creditors
7. Neuftec Issues Patent Infringement Proceedings in the UK Against Oxonica
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd.
9. Bristol-Myers Squibb Issues $1.6 Billion of Senior Notes
10. Issues MarketStats on KBLB, DGX, LH, BRLI, and ABT
11. VaxGen Issues Rebuttal to MedCap Letter
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
Breaking Biology Technology:
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
Breaking Biology News(10 mins):